UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 57

Sortiert nach

Mps1 Mediated Phosphorylation of Hsp90 Confers Renal Cell Carcinoma Sensitivity and Selectivity to Hsp90 Inhibitors

Cell reports (Cambridge), 2016-02, Vol.14 (4), p.872-884

2016

Volltextzugriff (PDF)

Gravin regulates centrosome function through PLK1

Molecular biology of the cell, 2018-03, Vol.29 (5), p.532-541

2018

Volltextzugriff (PDF)

PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma

Cancer research (Chicago, Ill.), 2005-02, Vol.65 (4), p.1406-1413

2005

Volltextzugriff (PDF)

Abi1 loss drives prostate tumorigenesis through activation of EMT and non-canonical WNT signaling

Cell communication and signaling, 2019-09, Vol.17 (1), p.120-120, Article 120

2019

Volltextzugriff (PDF)

Use of Replicating Oncolytic Adenoviruses in Combination Therapy for Cancer

Clinical cancer research, 2004-08, Vol.10 (16), p.5299-5312

2004

Volltextzugriff (PDF)

A novel hypoxia-inducible factor (HIF) activated oncolytic adenovirus for cancer therapy

Oncogene, 2003-04, Vol.22 (14), p.2065-2072

2003

Volltextzugriff (PDF)

Geldanamycin induces degradation of hypoxia-inducible factor 1α protein via the proteosome pathway in prostate cancer cells

Cancer research (Chicago, Ill.), 2002-05, Vol.62 (9), p.2478-2482

2002

Volltextzugriff (PDF)

Targeted cancer gene therapy using a hypoxia inducible factor-dependent oncolytic adenovirus armed with interleukin-4

Cancer research (Chicago, Ill.), 2007-07, Vol.67 (14), p.6872-6881

2007

Volltextzugriff (PDF)

Replicative oncolytic herpes simplex viruses in combination cancer therapies

Current gene therapy, 2004-03, Vol.4 (1), p.41

2004

Volltextzugriff (PDF)

Cancer Therapy with a Replicating Oncolytic Adenovirus Targeting the Hypoxic Microenvironment of Tumors

Clinical cancer research, 2004-12, Vol.10 (24), p.8603-8612

2004

Volltextzugriff (PDF)

Bay846, a new irreversible small molecule inhibitor of EGFR and Her2, is highly effective against malignant brain tumor models

Investigational new drugs, 2012-12, Vol.30 (6), p.2161-2172

2012

Volltextzugriff (PDF)

Replicative oncolytic adenoviruses in multimodal cancer regimens

Human gene therapy, 2003-07, Vol.14 (10), p.933-946

2003

Volltextzugriff (PDF)

Abstract 1088: Defining bone metastatic potential of Abi1 CRISPR prostate cancer cell lines

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.1088-1088

2018

Volltextzugriff (PDF)

Abstract 4466: The key role of Abi1 loss in dysregulating cell-cell adhesion during prostate cancer tumorigenesis

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.4466-4466

2017

Volltextzugriff (PDF)

Cancer Scene Investigation: how a cold virus became a tumor killer

Future oncology (London, England), 2005-04, Vol.1 (2), p.247-258

2005

Volltextzugriff (PDF)

Abstract 1403: Modeling of Abi1 loss using spheroid cultures to investigate mechanisms of prostate tumorigenesis

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.1403-1403

2018

Volltextzugriff (PDF)

Abi1 loss drives prostate tumorigenesis through activation of EMT and noncanonical WNT signaling

Journal of clinical oncology, 2019-03, Vol.37 (7_suppl), p.280-280

2019

Volltextzugriff (PDF)

Genetic and hypoxic regulation of angiogenesis in gliomas

Journal of neuro-oncology, 2004-11, Vol.70 (2), p.229-243

2004

Volltextzugriff (PDF)

Abstract 586: Targeted cancer gene-therapy using second-generation HIF-activated oncolytic adenoviruses with increased replication, oncolytic, and anti-tumor efficacy

Cancer research (Chicago, Ill.), 2010-04, Vol.70 (8_Supplement), p.586-586

2010

Volltextzugriff (PDF)

Development of an oncolytic herpes simplex virus using a tumor-specific HIF-responsive promoter

Cancer gene therapy, 2011-02, Vol.18 (2), p.123-134

2011

Volltextzugriff (PDF)

Second-generation HIF-activated oncolytic adenoviruses with improved replication, oncolytic, and anti-tumor efficacy

Gene therapy, 2010-07, Vol.17 (12), p.1430-1441

2010

Volltextzugriff (PDF)

Does gender affect the link between organizational citizenship behavior and performance evaluation?

Sex roles, 1999-09, Vol.41 (5-6), p.469-478

1999

Volltextzugriff (PDF)

Genetic and hypoxic regulation of angiogenesis in gliomas: Molecular pathogenesis of primary brain tumors

Journal of neuro-oncology, 2004, Vol.70 (2), p.229-243

2004

Volltextzugriff (PDF)

Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells

Cancer research (Chicago, Ill.), 2002-05, Vol.62 (9), p.2478-2482

2002

Volltextzugriff (PDF)

A National Examination of Processing Techniques and Staff Characteristics in Outdoor Behavioral Healthcare Programs

Journal of Therapeutic Wilderness Camping, 2003, Vol.3 (1), p.16

Post, Dawn Marie

2003

Volltextzugriff (PDF)

1 – 25 von 57

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(55)
Mit Volltextzugriff
(51)

Publikationsform

Artikel
(57)

Sprache

Englisch
(57)
Japanisch
(10)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Mps1 Mediated Phosphorylation of Hsp90 Confers Renal Cell Carcinoma Sensitivity and Selectivity to Hsp90 Inhibitors

Gravin regulates centrosome function through PLK1

PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma

Abi1 loss drives prostate tumorigenesis through activation of EMT and non-canonical WNT signaling

Use of Replicating Oncolytic Adenoviruses in Combination Therapy for Cancer

A novel hypoxia-inducible factor (HIF) activated oncolytic adenovirus for cancer therapy

Geldanamycin induces degradation of hypoxia-inducible factor 1α protein via the proteosome pathway in prostate cancer cells

Targeted cancer gene therapy using a hypoxia inducible factor-dependent oncolytic adenovirus armed with interleukin-4

Replicative oncolytic herpes simplex viruses in combination cancer therapies

Cancer Therapy with a Replicating Oncolytic Adenovirus Targeting the Hypoxic Microenvironment of Tumors

Bay846, a new irreversible small molecule inhibitor of EGFR and Her2, is highly effective against malignant brain tumor models

Replicative oncolytic adenoviruses in multimodal cancer regimens

Abstract 1088: Defining bone metastatic potential of Abi1 CRISPR prostate cancer cell lines

Abstract 4466: The key role of Abi1 loss in dysregulating cell-cell adhesion during prostate cancer tumorigenesis

Cancer Scene Investigation: how a cold virus became a tumor killer

Abstract 1403: Modeling of Abi1 loss using spheroid cultures to investigate mechanisms of prostate tumorigenesis

Abi1 loss drives prostate tumorigenesis through activation of EMT and noncanonical WNT signaling

Genetic and hypoxic regulation of angiogenesis in gliomas

Abstract 586: Targeted cancer gene-therapy using second-generation HIF-activated oncolytic adenoviruses with increased replication, oncolytic, and anti-tumor efficacy

Development of an oncolytic herpes simplex virus using a tumor-specific HIF-responsive promoter

Second-generation HIF-activated oncolytic adenoviruses with improved replication, oncolytic, and anti-tumor efficacy

Does gender affect the link between organizational citizenship behavior and performance evaluation?

Genetic and hypoxic regulation of angiogenesis in gliomas: Molecular pathogenesis of primary brain tumors

Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells

A National Examination of Processing Techniques and Staff Characteristics in Outdoor Behavioral Healthcare Programs

Suchergebnisse filtern